These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
122 related articles for article (PubMed ID: 6423926)
21. [Possibility of treatment in Chagas' disease]. Prata A AMB Rev Assoc Med Bras; 1978 Apr; 24(4):140-2. PubMed ID: 98813 [No Abstract] [Full Text] [Related]
30. The effect of nifurtimox in acute Chagas' infection. Wegner DH; Rohwedder RW Arzneimittelforschung; 1972 Sep; 22(9):1624-35. PubMed ID: 4630485 [No Abstract] [Full Text] [Related]
31. Adverse systemic reaction to benznidazole. Coronel MV; Frutos LO; Muñoz EC; Valle DK; Rojas DH Rev Soc Bras Med Trop; 2017; 50(1):145-147. PubMed ID: 28327820 [TBL] [Abstract][Full Text] [Related]
32. The use of steroids to prevent cutaneous reactions to benznidazole in patients with Chagas disease. Górgolas M; Robles I; Cabello A; Pérez-Tanoira R; Peremarch CP; Fernández-Roblas R; Williams F; Rincón JM Pathog Glob Health; 2013 Apr; 107(3):157-60. PubMed ID: 23683371 [TBL] [Abstract][Full Text] [Related]
33. Benznidazole, a drug used in Chagas' disease, ameliorates LPS-induced inflammatory response in mice. Pascutti MF; Pitashny M; Nocito AL; Guermonprez P; Amigorena S; Wietzerbin J; Serra E; Bottasso O; Revelli S Life Sci; 2004 Dec; 76(6):685-97. PubMed ID: 15567193 [TBL] [Abstract][Full Text] [Related]
34. Toxic Profile of Benznidazole in Patients with Chronic Chagas Disease: Risk Factors and Comparison of the Product from Two Different Manufacturers. Molina I; Salvador F; Sánchez-Montalvá A; Treviño B; Serre N; Sao Avilés A; Almirante B Antimicrob Agents Chemother; 2015 Oct; 59(10):6125-31. PubMed ID: 26195525 [TBL] [Abstract][Full Text] [Related]
35. Efficacy of thioctic acid in the therapy of peripheral diabetic neuropathy. Sachse G; Willms B Horm Metab Res Suppl; 1980; 9():105-7. PubMed ID: 6769773 [TBL] [Abstract][Full Text] [Related]
36. [Human American trypanosomiasis 90 years after its discovery by Carlos Chagas. II--Clinical aspects, physiopathology, diagnosis and treatment]. Pays JF Med Trop (Mars); 1999; 59(1):79-94. PubMed ID: 10472588 [TBL] [Abstract][Full Text] [Related]
37. [Clinical and parasitological findings and drug tolerance of 33 children with chronic Chagas' infection treated with Bay 2502]. Cichero JA; Segura E; Quatrochi JC Bol Chil Parasitol; 1969; 24(1):59-62. PubMed ID: 4983554 [No Abstract] [Full Text] [Related]
38. [Chronic Chagas' disease: effects of treatment nn the levels of antibodies to crude and partially purified Trypanosoma cruzi antigens]. Moretti E; Cervetta L; Basso B; Castro I; Santamarina N Bol Chil Parasitol; 1998; 53(1-2):3-9. PubMed ID: 9830716 [TBL] [Abstract][Full Text] [Related]
39. High frequency of adverse reactions and discontinuation with benznidazole treatment for chronic Chagas disease in Milan, Italy. Antinori S; Grande R; Bianco R; Traversi L; Cogliati C; Torzillo D; Repetto E; Corbellino M; Milazzo L; Galli M; Galimberti L Clin Infect Dis; 2015 Jun; 60(12):1873-5. PubMed ID: 25805302 [No Abstract] [Full Text] [Related]
40. Use of benznidazole to treat chronic Chagas' disease: a systematic review with a meta-analysis. Pérez-Molina JA; Pérez-Ayala A; Moreno S; Fernández-González MC; Zamora J; López-Velez R J Antimicrob Chemother; 2009 Dec; 64(6):1139-47. PubMed ID: 19819909 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]